The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.
With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
Using a mass spec-based proteogenomic approach, the researchers identified commonalities in neoantigen presentation across mantle cell lymphoma patients.
The groups said they hope their recommendations lead to higher-quality sequencing results in the lab and better care for cancer patients in the clinic.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.
This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.
Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.
In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay.
This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.